At Maui Derm NP+PA Summer 2026, Benjamin Ungar, MD, detailed how JAK inhibitors and oral minoxidil are reshaping hair loss treatment strategy.

Justin Gregory, MD, MPH, and Steve Zortman, MPH, RN, discuss the critical need for early detection and intervention in this underrepresented population.

Andrew Bzowyckyj, PharmD, explains the transition to the 2021 CKD-EPI equation and its implications for medication decisions.

During her SDPA Conference interview, Murase gave several more tips for skin management during pregnancy.

At Maui Derm Summer 2026, Hilary Baldwin, MD, used a single theoretical patient to illustrate how rosacea subtypes evolve and how treatment should follow suit.

Piotr Witkowski, MD, PhD, discusses the CD40L inhibitor’s efficacy in improving outcomes for patients with T1D undergoing islet transplant.

Earlier diagnosis is imperative for chronic liver disease; Stevan Gonzalez, MD, MS, explains how PCPs and community-based screening programs can help.

From tighter hemodynamic definitions to a first-in-class activin signaling inhibitor, a nearly 30-year PH veteran says the field has never had more to offer patients — or more complexity to manage.

In this SDPA interview, Murase provides tips for clinicians on conversations related to pregnancy, safety, and skin disease management.

In this episode, Dominic Sisti and Steve Levine talk with Arthur Caplan, PhD, about how the concept of brain death was built and why it still generates controversy 50 years later.

Gregory discusses his strategies for optimizing adult male patients’ typically infrequent clinic visits to identify and forestall T1D progression.

Sibeprenlimab preserved kidney function over 12 months in adults with IgA nephropathy in interim phase 3 VISIONARY trial findings.

A critical care NP and POCUS educator says point-of-care ultrasound competency is no longer optional for pulmonary and critical care APPs.

The supplemental New Drug Application for Arcutis’ roflumilast cream 0.05% (Zoryve) is for mild to moderate atopic dermatitis in those down to 3 months.

At Maui Derm NP+PA Summer 2026, Benjamin Ungar, MD, detailed how JAK inhibitors and oral minoxidil are reshaping hair loss treatment strategy.

Blumenthal discusses his presentation at the 10th Annual Heart in Diabetes meeting, in which he compared the current US and European dyslipidemia guidelines.

Heather O'Connell, PA-C, an allergy and asthma PA, describes how she uses clinical research and structured follow-up to shift patient thinking about the nose-lung connection, and why APPs bring a distinct advantage to that conversation.

Rajani Katta, MD, on navigating the diet-skin connection: evidence, myths, and clinical ownership.

Igudesman discusses her presentation at ENDO 2026, during which she covered the importance of managing obesity with lifestyle changes in patients with T1D.

John Giacona, PhD, PA-C, says identifying pulmonary hypertension early, distinguishing its type, and engaging critically with clinical evidence are paramount.

Stefan Weiss, MD, on recognizing mast cell disorders in the dermatology clinic and how avapritinib is reshaping treatment for indolent systemic mastocytosis.

Rishi Wadhera, MD, MPP, MPhil, discusses where the cardiometabolic care cascade is failing most consequentially at the 10th Annual Heart in Diabetes Meeting.

Hear Anu Lala, MD, discuss how she turned a moment of childhood fascination into a lifelong career of caring for patients.

First placebo-controlled phase 3 METRE-PL data show prevalent metabolic burden in familial partial lipodystrophy (FPLD) despite standard therapy.

This June episode of the podcast highlights one clinicians journey and experiences as a woman physician in the dermatology and rheumatology fields.

Matthew Zirwas, MD, on using dupilumab and lebrikizumab to guide patch testing decisions and the 2 most missed allergens in eczematous disease.

This episode covers the recent trial of the Signos weight loss platform, indicating weight loss that could challenge GLP-1 receptor agonists.

Panelists reached broad consensus that upfront dual oral combination therapy with an ERA and PDE5 inhibitor remains the foundational standard.

HCPLive previews Maui Derm NP+PA Summer 2026, covering sessions on atopic dermatitis, acne, psoriasis, pigmentation disorders, and more.

The CNP at Cleveland Clinic discusses how early recognition, cross-specialty collaboration, and extended patient engagement make APPs essential in the complex, long-term care of interstitial lung disease.

Peter Lio, MD, spoke at the RAD 2026 conference about the upcoming AAD pediatric guidelines for atopic dermatitis.

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

This episode covers recently released data regarding the Dexcom G7 and Eli Lilly’s investigational triple agonist retatrutide from ADA 2026.

Lance Sloan, MD, discusses his recent sub-analysis of the CATALYST trial, investigating whether hypercortisolism limits the efficacy of GLP-1s.

An EPICS-III study investigator discusses the mechanism of action of saroglitazar to treat patients with PBC.

View the top 6 trials to watch ahead of a star-studded ADA 2026.

Jeffrey Thiboutot, MD, discussed efficacy advantages seen in the trial at ATS 2026.

A study revealed adults with childhood onset atopic dermatitis may see greater limitations in career and educational options.

Jonathan Bernstein, MD, discusses remibrutinib, c-kit inhibitors, and the current limits of biomarker-guided decision-making in chronic spontaneous urticaria.

Jamie Wood, MD, discusses the impact of Afrezza’s recent FDA approval for pediatric patients with type 1 and type 2 diabetes.

A clinical forum discussed referral dynamics, access barriers, and patient health literacy challenges that shape biologic use in the real world.

FDA accepts the BLA for povetacicept in IgA nephropathy, supported by positive phase 3 RAINIER trial data.

This interview highlights key facts regarding HS in honor of Hidradenitis Suppurativa (HS) Awareness Week, featuring Kiera Booth, MD.

This segment of a Q&A interview with Kilian Eyerich, MD, PhD, highlights the signficance of the LumiNE phase 3 study on lebrikizumab.

At ATS 2026, Couillard discussed a win ratio analysis showing dupilumab significantly improved remission outcomes, particularly among patients with elevated eosinophils and FeNO.